This site became the new on June 19th. Learn more.
Show more Menu IMPORTANT: Listing of a study on this site does not reflect endorsement by the National Institutes of Health. Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu IMPORTANT: Talk with a trusted healthcare professional before volunteering for a study. Read more... Menu
Give us feedback

Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant Recipients.

This study has been completed.
Information provided by (Responsible Party):
Maria Coco, Montefiore Medical Center Identifier:
First received: December 15, 2005
Last updated: October 22, 2012
Last verified: October 2012

Patients with kidney failure have underlying bone disease at the time of transplant. Fractures of various bones can be as high as 22%. Medication required for the transplant plays a role in bone loss.

Bisphosphonates are used in the general population to treat bone loss of osteoporosis and steroid-induced bone loss. While previous studies, using various bisphosphonates, have shown preservation of bone mineral density in renal transplant recipients, we have demonstrated that pamidronate, a second generation bisphosphonate, is associated with low bone turnover while still preserving bone mineral density. Improved bone mineral density is associated with decreased fracture risk in the general population, while low bone turnover may be associated with increased fracture in dialysis patients.

The purpose of this study is to determine whether risedronate, a third generation bisphosphonate, is effective in preserving bone density when given prophylactically following renal transplantation and whether it is associated with low bone turnover at one year following renal transplantation.

Condition Intervention
Renal Transplant Osteodystrophy Drug: risedronate 35 mg weekly vs placebo

Study Type: Interventional
Study Design: Allocation: Randomized
Intervention Model: Parallel Assignment
Masking: Triple (Participant, Care Provider, Investigator)
Primary Purpose: Treatment
Official Title: Randomized Trial of Risedronate to Prevent Bone Loss in Renal Transplant

Resource links provided by NLM:

Further study details as provided by Maria Coco, Montefiore Medical Center:

Primary Outcome Measures:
  • differences in bone mineral density between the two arms [ Time Frame: baseline, 6 months and 12 months ]
    measurement of BMD

Secondary Outcome Measures:
  • analyzing bone histomorphometry bewtween the two arms [ Time Frame: baseline and 12 months ]
    bone biopies at baseline and 12 months are compared between the two arms

Enrollment: 60
Study Start Date: October 2002
Study Completion Date: July 2008
Primary Completion Date: July 2008 (Final data collection date for primary outcome measure)
Arms Assigned Interventions
Experimental: bisphosphonate arm
subjects received bisphosphonate for one year
Drug: risedronate 35 mg weekly vs placebo
Placebo Comparator: subjects received placebo
subjects received placebo for 1 year
Drug: risedronate 35 mg weekly vs placebo

Detailed Description:
Participants who receive a living donor kidney transplant undergo a bone biopsy at the time of kidney transplant and after one year of protocol. Once adequate kidney function is established, both groups take by mouth a weekly capsule (the control group has a placebo; the treatment group has risedronate 35 mg). Both groups undergo baseline, 6 month and 12 month DEXA bone mineral density scans. Both groups undergo bone hormonal studies at regular intervals.

Ages Eligible for Study:   18 Years and older   (Adult, Senior)
Sexes Eligible for Study:   All
Accepts Healthy Volunteers:   No

Inclusion Criteria:

  • Adults with end stage renal disease who are undergoing living donor kidney transplantation
  Contacts and Locations
Choosing to participate in a study is an important personal decision. Talk with your doctor and family members or friends about deciding to join a study. To learn more about this study, you or your doctor may contact the study research staff using the Contacts provided below. For general information, see Learn About Clinical Studies.

Please refer to this study by its identifier: NCT00266708

United States, New York
Montefiore Medical Center
Bronx, New York, United States, 10467
Sponsors and Collaborators
Montefiore Medical Center
Principal Investigator: Maria Coco, MD, MS Montefiore Medical Center
  More Information

Responsible Party: Maria Coco, Principal Investigator, Montefiore Medical Center Identifier: NCT00266708     History of Changes
Other Study ID Numbers: 02-08-224
Study First Received: December 15, 2005
Last Updated: October 22, 2012

Keywords provided by Maria Coco, Montefiore Medical Center:
renal transplant
post-transplant osteoporosis

Additional relevant MeSH terms:
Risedronate Sodium
Etidronic Acid
Calcium Channel Blockers
Membrane Transport Modulators
Molecular Mechanisms of Pharmacological Action
Bone Density Conservation Agents
Physiological Effects of Drugs processed this record on August 21, 2017